Dopamine suppresses osteoclast differentiation via cAMP/PKA/CREB pathway

Wang, Lufei; Han, Lichi; Xue, Peng; Hu, Xinran; Wong, Sing‐Wai; Deng, Meng; Tseng, Henry; Huang, Bowen; Ko, Ching‐Chang

doi:10.1016/j.cellsig.2020.109847

Cited by 27 publications

(30 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among RTKs, there was increased phosphorylation of M-CSFR, InsR, ROR2, c-Ret and PDGFRβ, whose expression is directly associated with GCTB promotion [ 34 , 35 ] and osteoblast or osteoclast differentiation [ 36 , 37 , 38 ]. Similar processes related to bone remodeling are also associated with the highly phosphorylated downstream signaling proteins c-Jun, eNOS, HSP60, GSK3α/β, CREB, ERK1/2 and HSP27 [ 39 , 40 , 41 , 42 , 43 , 44 ]. This specific signaling profile typical of untreated GCTB tissue is subject to change after denosumab treatment.…”

Section: Discussionmentioning

confidence: 99%

New Target for Precision Medicine Treatment of Giant-Cell Tumor of Bone: Sunitinib Is Effective in the Treatment of Neoplastic Stromal Cells with Activated PDGFRβ Signaling

Mahdal

Neradil

Múdrý

et al. 2021

Cancers

View full text Add to dashboard Cite

Giant-cell tumor of bone (GCTB) is an intermediate type of primary bone tumor characterized by locally aggressive growth with metastatic potential. The aim of this study was to identify new druggable targets among the cell signaling molecules involved in GCTB tumorigenesis. Profiles of activated signaling proteins in fresh-frozen tumor samples and tumor-derived cell lines were determined using phosphoprotein arrays. Analysis of the obtained data revealed epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor beta (PDGFRβ) as potential targets, but only the PDGFR inhibitor sunitinib caused a considerable decrease in stromal cell viability in vitro. Furthermore, in the case of a 17-year-old patient suffering from GCTB, we showed that the addition of sunitinib to the standard treatment of GCTB with the monoclonal antibody denosumab resulted in the complete depletion of multinucleated giant cells and mononuclear stromal cells in the tumor tissue. To summarize, the obtained data showed that a specific receptor tyrosine kinase (RTK) signaling pattern is activated in GCTB cells and plays an important role in the regulation of cell proliferation. Thus, activated RTKs and their downstream signaling pathways represent useful targets for precision treatment with low-molecular-weight inhibitors or with other types of modern biological therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

New Target for Precision Medicine Treatment of Giant-Cell Tumor of Bone: Sunitinib Is Effective in the Treatment of Neoplastic Stromal Cells with Activated PDGFRβ Signaling

Mahdal

Neradil

Múdrý

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…These data suggest that catecholamine increase may possibly regulate osteoclast signaling. Dopamine/DR signaling does have an important regulatory role in osteoclasts differentiation and function but this is dopamine-receptor specific (Nakashioya et al, 2011;Hanami et al, 2013a;Hanami et al, 2013b;Yang et al, 2016;Motyl et al, 2017;Handa et al, 2019;Wang et al, 2021). No significant effect on osteoclast differentiation and function was found when human and mouse monocyte cultures were treated with a DR1-agonist (Hanami et al, 2013a;Hanami et al, 2013b;Yang et al, 2016;Wang et al, 2021; Table 3).…”

Section: Mao Inhibitors: Catecholamines Regulate Osteoclastogenesismentioning

confidence: 99%

“…Dopamine/DR signaling does have an important regulatory role in osteoclasts differentiation and function but this is dopamine-receptor specific (Nakashioya et al, 2011;Hanami et al, 2013a;Hanami et al, 2013b;Yang et al, 2016;Motyl et al, 2017;Handa et al, 2019;Wang et al, 2021). No significant effect on osteoclast differentiation and function was found when human and mouse monocyte cultures were treated with a DR1-agonist (Hanami et al, 2013a;Hanami et al, 2013b;Yang et al, 2016;Wang et al, 2021; Table 3). Treatment of cultures with a DR1-antagonist had primarily no effect on osteoclastogenesis (Hanami et al, 2013a;Yang et al, 2016;Wang et al, 2021), although one study did show DR1antagonist inhibition of osteoclastogenesis (Nakashioya et al, 2011).…”

Section: Mao Inhibitors: Catecholamines Regulate Osteoclastogenesismentioning

confidence: 99%

“…No significant effect on osteoclast differentiation and function was found when human and mouse monocyte cultures were treated with a DR1-agonist (Hanami et al, 2013a;Hanami et al, 2013b;Yang et al, 2016;Wang et al, 2021; Table 3). Treatment of cultures with a DR1-antagonist had primarily no effect on osteoclastogenesis (Hanami et al, 2013a;Yang et al, 2016;Wang et al, 2021), although one study did show DR1antagonist inhibition of osteoclastogenesis (Nakashioya et al, 2011). In contrast, human and mouse osteoclast differentiation and function were significantly inhibited with DR2-like agonists.…”

Section: Mao Inhibitors: Catecholamines Regulate Osteoclastogenesismentioning

confidence: 99%

“…In contrast, human and mouse osteoclast differentiation and function were significantly inhibited with DR2-like agonists. In addition, dopamine-mediated inhibition of osteoclastogenesis was negated by DR2-like receptor antagonists (Hanami et al, 2013a;Hanami et al, 2013b;Yang et al, 2016;Handa et al, 2019;Wang et al, 2021). Dopamine regulation of osteoclastogenesis through DR2 signaling inhibited cAMP activation and reduced activation of PKA and CREB signaling (Handa et al, 2019).…”

Section: Mao Inhibitors: Catecholamines Regulate Osteoclastogenesismentioning

confidence: 99%

See 2 more Smart Citations

Monoamine Oxidase Inhibitors: A Review of Their Anti-Inflammatory Therapeutic Potential and Mechanisms of Action

Ostadkarampour

Putnins

2021

Front. Pharmacol.

View full text Add to dashboard Cite

Chronic inflammatory diseases are debilitating, affect patients’ quality of life, and are a significant financial burden on health care. Inflammation is regulated by pro-inflammatory cytokines and chemokines that are expressed by immune and non-immune cells, and their expression is highly controlled, both spatially and temporally. Their dysregulation is a hallmark of chronic inflammatory and autoimmune diseases. Significant evidence supports that monoamine oxidase (MAO) inhibitor drugs have anti-inflammatory effects. MAO inhibitors are principally prescribed for the management of a variety of central nervous system (CNS)-associated diseases such as depression, Alzheimer’s, and Parkinson’s; however, they also have anti-inflammatory effects in the CNS and a variety of non-CNS tissues. To bolster support for their development as anti-inflammatories, it is critical to elucidate their mechanism(s) of action. MAO inhibitors decrease the generation of end products such as hydrogen peroxide, aldehyde, and ammonium. They also inhibit biogenic amine degradation, and this increases cellular and pericellular catecholamines in a variety of immune and some non-immune cells. This decrease in end product metabolites and increase in catecholamines can play a significant role in the anti-inflammatory effects of MAO inhibitors. This review examines MAO inhibitor effects on inflammation in a variety of in vitro and in vivo CNS and non-CNS disease models, as well as their anti-inflammatory mechanism(s) of action.

show abstract

Applications of Polydopamine in Implant Surface Modification

Ma,

Wang,

et al. 2023

Macromolecular Bioscience

View full text Add to dashboard Cite

There is great clinical demand for orthopedic and dental implant surface modification methods to prevent osseointegration failure and improve implant biological functions. Notably, dopamine (DA) can be polymerized to form polydopamine (PDA), which is similar to the adhesive proteins secreted by mussels, to form a stable bond between the bone surface and implants. Therefore, PDA has the potential to be used as an implant surface modification material with good hydrophilicity, roughness, morphology, mechanical strength, biocompatibility, antibacterial activity, cellular adhesion, and osteogenesis. In addition, PDA degradation releases DA into the surrounding microenvironment, which is found to play an important role in regulating DA receptors on both osteoblasts and osteoclasts during the bone remodeling process. Furthermore, the adhesion properties of PDA suggest its use as an intermediate layer in assisting other functional bone remodeling materials, such as nanoparticles, growth factors, peptides, and hydrogels, to form “dual modifications.” The purpose of this review is to summarize the recent progress in research on PDA and its derivatives as orthopedic and dental implant surface modification materials and to analyze the multiple functions of PDA.

show abstract

Dopamine suppresses osteoclast differentiation via cAMP/PKA/CREB pathway

Cited by 27 publications

References 37 publications

New Target for Precision Medicine Treatment of Giant-Cell Tumor of Bone: Sunitinib Is Effective in the Treatment of Neoplastic Stromal Cells with Activated PDGFRβ Signaling

New Target for Precision Medicine Treatment of Giant-Cell Tumor of Bone: Sunitinib Is Effective in the Treatment of Neoplastic Stromal Cells with Activated PDGFRβ Signaling

Monoamine Oxidase Inhibitors: A Review of Their Anti-Inflammatory Therapeutic Potential and Mechanisms of Action

Applications of Polydopamine in Implant Surface Modification

Contact Info

Product

Resources

About